OraSure Technologies (OSUR) Expected to Announce Earnings on Wednesday
OraSure Technologies (NASDAQ:OSUR) is anticipated to release its Q4 2025 earnings after the market closes on Wednesday, February 25th, 2026. Analysts are forecasting earnings of ($0.17) per share on revenue of $26.443 million. The company's stock currently holds a "Reduce" consensus rating from Wall Street, with an average price target of $3.00.
OraSure to Launch OraQuick™ HIV Self-Test in Canada
OraSure Technologies, Inc. announced that its OraQuick™ HIV Self-Test has received a license from Health Canada, making it the country's first oral HIV self-test. This product allows individuals to test for HIV-1 and HIV-2 antibodies with an oral swab, getting results in 20 minutes, and aims to expand access to testing in Canada, where thousands remain undiagnosed. St. Michael’s Hospital (Unity Health Toronto) will be the exclusive distributor of the test in Canada.
OraSure makes job cuts as it ‘rebalances’ for future growth
OraSure Technologies, a Bethlehem-based biopharmaceutical manufacturer, is laying off a "single-digit percentage" of its global workforce, affecting about 10 positions in the Lehigh Valley. These cuts are part of a strategic restructuring to rebalance its cost structure and support investments in its product roadmap, including anticipated launches of its CT/NG molecular self-test and Colli-Pee urine collection device. The company also announced that its OraQuick HIV Self-Test has received a license from Health Canada.
OraSure to Launch OraQuick™ HIV Self-Test in Canada
OraSure Technologies, Inc. has announced that its OraQuick™ HIV Self-Test has received a license from Health Canada, making it Canada's first oral HIV self-test. This product allows individuals to determine their HIV status in approximately 20 minutes from an oral swab. This initiative aims to expand access to HIV testing, reduce stigma, and improve early diagnosis and linkage to care, especially in provinces with higher HIV rates like Manitoba and Saskatchewan.
OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its fourth quarter 2025 earnings conference call for February 25, 2026, at 5 p.m. ET. A webcast of the call will be available on the investor relations page of the company's website. OraSure is a leader in developing, manufacturing, and distributing rapid diagnostic tests and sample collection devices.
Oral HIV self-test approved for sale, advocates say it's key to elimination
An oral, at-home HIV test, the OraQuick HIV self-test, has been approved for distribution in Canada, offering a less invasive alternative to blood-based tests. Experts believe this development is crucial for reaching Canada's goal of eliminating HIV as a public health threat by 2030, especially for communities facing health inequities. However, sustained government funding for distribution through front-line agencies will be essential to ensure accessibility and affordability.
OraSure (OSUR) Gains Health Canada Approval for OraQuick HIV Sel
OraSure Technologies (OSUR) has received Health Canada approval for its OraQuick HIV Self-Test, making it the first oral HIV self-test available in Canada. Despite this significant product advancement, the company faces financial challenges including negative earnings growth and declining margins. While strategically positioned for market expansion, OraSure needs to address its financial health to fully capitalize on new opportunities.
Canada’s first oral HIV self-test lets people check at home
OraSure Technologies Inc. has received Health Canada approval for its OraQuick™ HIV Self-Test, making it Canada's first oral HIV self-test. This rapid antibody test detects HIV-1 and HIV-2 and provides results in approximately 20 minutes, allowing for private at-home or community-based testing. St. Michael’s Hospital (Unity Health Toronto) will be the exclusive Canadian distributor to ensure national access, aiming to reach thousands of undiagnosed individuals in Canada.
OraSure to Launch OraQuick™ HIV Self-Test in Canada
OraSure Technologies, Inc. announced that its OraQuick™ HIV Self-Test has received a license from Health Canada, making it Canada's first oral HIV self-test. This product allows individuals to determine their HIV status privately using a simple oral swab, with results in as little as 20 minutes. St. Michael’s Hospital (Unity Health Toronto) will be the exclusive distributor in Canada, aiming to expand access to HIV testing and help undiagnosed individuals connect with care.
OraSure’s HIV self-test receives Health Canada license
OraSure Technologies' OraQuick HIV Self-Test has received a license from Health Canada, making it the first approved oral HIV self-test in the country. This development, which provides results in 20 minutes, aims to improve early diagnosis and access to care, especially for the estimated 7,000+ undiagnosed individuals in Canada. Meanwhile, OraSure is also facing a challenge from activist investor Altai Capital Management regarding its share price performance and strategic direction, as Altai intends to nominate two candidates for the company's board.
OraSure Technologies, Inc. Schedules Fourth Quarter 2025 Earnings Conference Call for February 25, 2026
OraSure Technologies, Inc. has scheduled its fourth-quarter 2025 earnings conference call for February 25, 2026, at 5 p.m. ET. The call will discuss financial results and business updates, accessible via webcast on the company's investor relations page. The article also provides current insider trading activity, revenue data indicating a decrease, and details on hedge fund activity for OSUR.
OSUR: New STI Testing Submissions Will Drive Future Shareholder Value
OraSure Technologies' stock (OSUR) has seen a modestly revised price target of US$4.50 by analysts, with its fair value remaining largely unchanged despite a 27.6% drop over the last year. The company recently submitted two applications to the U.S. FDA for rapid molecular self-tests for STIs and a urine collection device, targeting a US$1.5 billion market. Activist investor Altai Capital Management is seeking board representation due to concerns about share price performance and capital allocation.
Lehigh Valley manufacturer conducts layoffs as it prepares to launch products
OraSure Technologies is laying off 10 employees at its Bethlehem headquarters as part of a strategic transformation to rebalance its cost structure. The diagnostic test kit manufacturer anticipates launching two new products after FDA approval and has been strengthening its business foundation since 2022 to accelerate profitable growth. Despite the layoffs, the company's shares were flat on Friday but are down about 30% over the last year.
OraSure Technologies (NASDAQ:OSUR) Share Price Passes Above 200 Day Moving Average - What's Next?
OraSure Technologies (NASDAQ:OSUR) stock recently traded above its 200-day moving average but is facing cautious analyst sentiment and has negative profitability. Despite beating EPS estimates in its last quarter, revenue missed, and the company maintains a "Reduce" average rating from analysts with institutional ownership around 93.5%. The article provides a detailed financial overview including price action, analyst targets, and institutional investor activity.
OraSure files for FDA review of molecular self-test & Colli-Pee device
OraSure Technologies has submitted an application to the FDA for review of its OraQuick® HCV molecular self-test. The company also announced that its Colli-Pee device, for the at-home collection of first-void urine, will be evaluated in a study by the National Cancer Institute. These developments suggest OraSure is expanding its offerings in at-home diagnostic solutions.
Altai Capital nominates two directors to OraSure's board
Altai Capital has nominated two individuals to serve on OraSure's board of directors. This move by the investment firm suggests an intent to influence the company's governance or strategic direction.
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
OraSure Technologies confirmed that Altai Capital has nominated two candidates, including its founder Rishi Bajaj, for election to the Company's Board of Directors at its 2026 Annual Meeting. OraSure's Board has engaged with Altai Capital previously, interviewed Mr. Bajaj, but decided to appoint an alternative candidate. The company emphasized its strong, independent, and engaged Board, noting significant refreshment since 2022.
The Truth About OraSure Technologies: Is This ‘Boring’ Test Maker Your Next Viral Money Play?
OraSure Technologies (OSUR), a company specializing in diagnostic tests and specimen collection, is analyzed for its investment potential. Although not a "sexy" brand like AI or crypto, its relevance in at-home testing and public health could make it a sleeper pick for investors interested in under-the-radar healthcare plays. The article compares OraSure to larger competitor Abbott Laboratories, highlighting OraSure's niche focus and agility against its current low trading price post-COVID highs, suggesting it's a "prove it" stock for those willing to do their homework.
Altai pushes OraSure (NASDAQ: OSUR) board shakeup with two nominees at 2026 annual meeting
Altai Capital Management, holding 5.2% of OraSure Technologies (OSUR), has launched an activist campaign to elect two nominees, John Bertrand and Rishi Bajaj, to the company's board at the 2026 Annual Meeting. Altai cites OraSure's significant share price underperformance and dissatisfaction with its strategic and capital allocation decisions as reasons for the proposed board shakeup. The firm believes new directors with specialized expertise in investment management, healthcare technology, and AI are necessary to improve the company's long-term value.
Altai Capital nominates two directors for OraSure Technologies board By Investing.com
Altai Capital has nominated two candidates, including its founder Rishi Bajaj, for election to OraSure Technologies' board of directors at its 2026 annual meeting. OraSure, a diagnostic test maker with a market cap of $199 million, has seen its stock decline 28% in the past year despite a recent recovery, and its board has previously interviewed Bajaj but ultimately appointed an alternative candidate. The company, which holds more cash than debt, is currently experiencing significant cash burn with a negative EBITDA of $52.21 million.
Altai Capital nominates two directors to OraSure board amid concerns By Investing.com
Altai Capital Management, holding 5.2% of OraSure Technologies (NASDAQ:OSUR), has nominated John Bertrand and Rishi Bajaj to the company's board of directors for the 2026 Annual Meeting. This action stems from Altai's concerns regarding OraSure's "extremely poor strategy and capital allocation decisions" and underperforming share price. The firm believes specialized expertise and direct shareholder perspective are crucial to improve the company's trajectory.
5.2% OraSure shareholder pushes new directors with AI, tech focus
Altai Capital Management, a significant shareholder of OraSure Technologies (OSUR) with a 5.2% stake, has nominated two candidates, John Bertrand and Rishi Bajaj, to the company's Board of Directors. Altai believes the current board has failed to deliver shareholder value due to poor strategic and capital allocation decisions. The nominees aim to bring specialized expertise in AI, healthcare technology, investment management, and a direct shareholder perspective to drive value creation.
Orasure Technologies Confirms Receipt Of Director Nominations From Altai Capital
Orasure Technologies has confirmed that it received director nominations from Altai Capital. The article is a brief news update from Reuters, indicating that the information is related to management activities concerning OSUR.
Altai Capital nominates two directors for OraSure Technologies board By Investing.com
Altai Capital has nominated two candidates, including its founder Rishi Bajaj, for election to OraSure Technologies' board of directors at the 2026 annual meeting. This move comes despite OraSure's efforts in board refreshment and its earlier decision to appoint an alternative candidate over Bajaj. OraSure Technologies, a diagnostic test maker, is currently burning through cash, holding negative EBITDA of $52.21 million over the last twelve months.
New leadership duo joins IAS to steer global digital ad quality push
Integral Ad Science (IAS) has announced the appointment of Marc Grabowski as Chief Operating Officer and Srishti Gupta as Chief Product Officer, effective September 16, 2024. These strategic hires aim to strengthen IAS's global commercial operations and product development across various channels including social media, the open web, and Connected TV. Both executives will report directly to CEO Lisa Utzschneider, leveraging their extensive backgrounds from companies like Oracle Advertising, Criteo, Rokt, and Amazon to drive innovation and customer focus.
Altai Capital nominates two directors to OraSure's board (update) (OSUR:NASDAQ)
Altai Capital, holding a 5.2% stake in OraSure Technologies (OSUR), has nominated two candidates, John Bertrand and Rishi Newsletters, for election to OraSure's board of directors. Following this announcement, OraSure's stock saw a 3.2% increase. An update indicates that OraSure has commented on the nominations.
Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors
Altai Capital Management, a major shareholder in OraSure Technologies, Inc. (NASDAQ: OSUR), has nominated John Bertrand and Rishi Bajaj for election to OraSure's Board of Directors. This move comes after Altai expressed serious concerns about OraSure's significant share price underperformance and the current board's inability to drive value. Altai believes the nominated candidates will bring essential expertise in investment management, technology, healthcare technology, and artificial intelligence to address the company's strategic and capital allocation issues.
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
OraSure Technologies has confirmed that Altai Capital nominated two candidates, including founder Rishi Bajaj, for election to its Board of Directors at the 2026 Annual Meeting of Stockholders. OraSure's Board had previously engaged with Altai, interviewed Bajaj, and ultimately appointed an alternative director. The company emphasizes its strong, independent, and refreshed Board, advising shareholders that no action is required at this time.
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
OraSure Technologies confirmed that Altai Capital has nominated two candidates, including its founder Rishi Bajaj, for election to the Company’s Board of Directors at its 2026 Annual Meeting of Stockholders. The company stated that its Board has previously engaged with Altai, interviewed Bajaj, and decided on an alternative candidate. OraSure shareholders are not required to take any action at this time, as the nominations will be reviewed by the Nominating and Corporate Governance Committee and the Board, with recommendations to be presented in an upcoming proxy statement.
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
OraSure Technologies, Inc. has confirmed receiving director nominations from Altai Capital, including its founder Rishi Bajaj, for the 2026 Annual Meeting of Stockholders. The company's board has engaged with Altai Capital previously and decided to appoint an alternative candidate. OraSure emphasizes its strong, independent board composition, with significant refreshment since 2022, and advises shareholders that no action is required at this time.
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device
OraSure Technologies (OSUR) has submitted two applications to the FDA for approval of new at-home tests for sexually transmitted infections (STIs): a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae, and the Colli-Pee device for at-home urine sample collection. These submissions are part of OraSure's strategy to decentralize diagnostics and provide more accessible, convenient, and private STI testing options. The company believes these advancements will support recurring revenues and strengthen its position in the growing at-home diagnostics market, which is valued at $6.91 billion in 2025 and is expected to grow significantly.
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device
OraSure Technologies (OSUR) has submitted two applications to the FDA for at-home diagnostic tests for sexually transmitted infections (STIs): a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG), and the Colli-Pee device for at-home urine sample collection. These submissions are part of OraSure's strategy to decentralize diagnostics, making testing more accessible and convenient for patients. The company aims to capitalize on the growing home diagnostics market and strengthen its position in the at-home STI testing space.
OraSure seeking FDA approval for pair of products
OraSure Technologies is seeking FDA approval for two new products: a rapid molecular self-test for Chlamydia and gonorrhea, and the Colli-Pee device for at-home urine collection for STIs. These submissions are part of the company's strategy to decentralize diagnostics and make care more accessible. The company also faces a potential boardroom challenge from Altai Capital Management.
OraSure submits FDA applications for rapid STI test and collection device
OraSure Technologies has submitted two applications to the FDA for a rapid molecular self-test for Chlamydia and Gonorrhea, and an at-home urine collection device for STIs, aiming to decentralize diagnostics. The company sees a total addressable market exceeding $1.5 billion for CT/NG testing. These submissions come alongside recent financial performance exceeding EPS expectations, and shareholder activism regarding company performance.
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review
OraSure Technologies, Inc. (NASDAQ: OSUR) has submitted applications to the FDA for its rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) and its Colli-Pee™ at-home urine collection device for STIs. These submissions mark significant progress in the company's innovation strategy, aiming to decentralize diagnostics and provide more accessible and convenient testing solutions. The CT/NG self-test, leveraging the Sherlock platform, offers results in approximately 30 minutes, targeting a market estimated at over $1.5 billion, while the Colli-Pee™ device addresses patient preferences for private at-home urine collection.
OraSure submits FDA applications for rapid STI test and collection device
OraSure Technologies has submitted two applications to the FDA for a rapid molecular self-test for Chlamydia and Gonorrhea and a Colli-Pee at-home urine collection device for STIs. The company's stock, OSUR, is currently trading at $2.38 and is considered undervalued by InvestingPro analysis. These submissions mark significant progress in OraSure's efforts to decentralize diagnostics.
OraSure Seeks FDA Clearance for New STI Tests
OraSure Technologies is seeking FDA clearance for a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae, and an at-home urine collection device for sexually transmitted infections (STIs). These submissions aim to expand decentralized STI diagnostics, targeting a U.S. testing market valued over $1.5 billion, and reinforce OraSure's leadership in at-home testing solutions. Despite these strategic initiatives, an AI analysis from TipRanks rates OSUR stock as Neutral due to financial performance challenges.
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review
OraSure Technologies, Inc. announced the submission of two applications to the U.S. FDA for clearance of its rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) and its Colli-Pee™ at-home urine collection device for STIs. These submissions are part of OraSure's strategy to decentralize diagnostics and enhance access to convenient, private, and personalized care. The company estimates a total addressable market of over $1.5 billion for CT/NG testing, highlighting a significant opportunity for market expansion with its new self-test and collection device.
OraSure Technologies, Inc. Submits FDA Applications for Rapid Self-Test for STIs and At-Home Urine Collection Device
OraSure Technologies, Inc. has submitted two applications to the U.S. FDA for approval of a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae, and its Colli-Pee™ at-home urine collection device for STIs. These submissions aim to increase diagnostic accessibility, convenience, and privacy, expanding OraSure's leadership in decentralized diagnostic solutions. The rapid self-test provides results in about 30 minutes, and the market for CT/NG testing is estimated to exceed $1.5 billion.
OraSure Technologies, Inc. Submits FDA Applications for Rapid Self-Test for STIs and At-Home Urine Collection Device
OraSure Technologies, Inc. has submitted applications to the FDA for a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae, as well as an at-home urine collection device, Colli-Pee™. These submissions aim to enhance diagnostic accessibility and convenience for STIs, with the rapid self-test providing results in about 30 minutes. OraSure sees a significant market opportunity in decentralizing diagnostics currently handled by centralized labs.
OraSure Technologies Inc Submits FDA Applications for Diagnostic Devices
OraSure Technologies Inc. (OSUR) announced on January 5, 2026, the submission of FDA applications for its rapid molecular self-test and Colli-Pee device. The CT/NG self-test provides results in 30 minutes in an OTC format, and the Colli-Pee device facilitates at-home urine collection for STIs, targeting a potential $1.5 billion market for rapid CT/NG testing and aiming to expand diagnostic access.
Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors
Altai Capital Management, a significant shareholder of OraSure Technologies (NASDAQ: OSUR), plans to nominate John Bertrand and Rishi Bajaj to the OraSure Board of Directors. Altai attributes OraSure's recent share price underperformance to poor strategic decisions and advises that these candidates would bring valuable expertise and a shareholder perspective. The firm's criticisms include the company's failure to turn around core products post-COVID-19, ill-timed investments, and inefficient cash deployment leading to declining revenue.
Hedge fund confirms boardroom battle brewing at OraSure
Altai Capital Management, a California-based hedge fund owning over 5% of OraSure's common stock, plans to nominate two directors to OraSure's board at the 2026 annual meeting, citing the company's significant underperformance and strategic missteps. OraSure acknowledged the move, stating it had previously considered and rejected one of Altai's nominees for a board position. The company defends its current actions to improve performance, including consolidating operations and exiting unprofitable business lines, as its stock has significantly declined since 2020.
Altai Capital to nominate two board candidates at OraSure Technologies
Altai Capital plans to nominate two candidates, including its founder Rishi Bajaj, to OraSure Technologies' Board of Directors for the 2026 Annual Meeting, citing concerns about the company's performance. OraSure, a diagnostic test maker, confirmed the notification and highlighted recent board changes, ongoing strategic initiatives, and strong financial health with $216 million in cash and no debt as of Q3 2025. Despite a significant year-to-date share decline, InvestingPro data suggests the company is undervalued, and management has been aggressively buying back shares.
Altai Capital to nominate directors to OraSure board amid concerns
Altai Capital Management, which owns 5.2% of OraSure Technologies (NASDAQ:OSUR), plans to nominate two directors to the company's board due to concerns over its performance and strategic direction. The investment firm cited a 37.5% share price decline, poor execution post-COVID-19 revenue decrease, "ill-timed, venture-like investments," and depletion of cash. Altai's nominees include John Bertrand and Rishi Bajaj, aiming to address what they perceive as significant underperformance and refusal to consider alternative value creation strategies.
OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates
OraSure Technologies has confirmed that Altai Capital intends to nominate two director candidates for its 2026 Annual Meeting. OraSure's Board had previously evaluated and declined to appoint one of the nominees, Rishi Bajaj, and states it has made efforts to engage further with Altai. The company emphasizes its commitment to shareholder value through a strong Board, strategic initiatives, a share repurchase program, and insider stock purchases.
Altai Capital to nominate two board candidates at OraSure Technologies By Investing.com
Altai Capital plans to nominate two candidates, including founder Rishi Bajaj, to OraSure Technologies' Board of Directors at its 2026 Annual Meeting, citing concerns over the company's performance. OraSure, a diagnostic test maker, confirmed the notification and highlighted recent board changes and strategic initiatives to improve its position. Despite undervalued stock according to InvestingPro, the company shows strong cash with no debt and management aggressively buying back shares.
OraSure Technologies Confirms Altai Capital's Nomination of Board Candidates Ahead of 2026 Annual Meeting
OraSure Technologies confirmed that Altai Capital intends to nominate two candidates, including its founder Rishi Bajaj, for election to the Board of Directors at the 2026 Annual Meeting. OraSure's Board emphasized its commitment to shareholder value, highlighting recent board refreshment and ongoing strategies to enhance growth and profitability, while noting Altai Capital has not accepted invitations for further dialogue. The company also detailed its strong financial position, a $40 million share repurchase program, and upcoming advancements in its product portfolio.
OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates
OraSure Technologies confirmed that Altai Capital intends to nominate two director candidates, including its founder Rishi Bajaj, for the 2026 annual meeting. OraSure's board had previously declined to appoint Bajaj and highlighted recent changes and strategic initiatives to enhance shareholder value. The company also announced a $40 million share repurchase program and ongoing FDA submissions.
Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors
Altai Capital Management, a significant shareholder of OraSure Technologies, Inc. (NASDAQ: OSUR), has announced its intention to nominate two candidates, John Bertrand and Rishi Bajaj, for election to OraSure's Board of Directors. This action stems from concerns over OraSure's sustained share price underperformance and the Board's perceived failure to implement effective strategies for value creation. Altai believes these nominees will introduce crucial expertise and a shareholder-focused perspective that is currently absent from the Board.
